Reports of recovery from disease due to MGN-3
|
Chronic hepatitis,Chronic Hepatitis, Type B, and Liver Cancer（1）（2）,Chronic C type virus hepatitis（1）（2）（3）,Chronic C type virus hepatitis,stomach cancer,Cirrhosis,,Chronic hepatitis C, liver cancer（1）（2）,Chronic Hepatitis, Type C
Diabetes（1）,（2）,Diabetes (NIDDM),Diabetes (NIDDM), asthma
Breast Cancer（1）（2）（3）（4）（5）（6）（7）（8）（9）,Breast cancer (metastasis in the left neck lymph node) ,Breast cancer and metastases in the brain and lung
Hepatitis C（1）（2）｜Hepatitis C→liver cancer
Prostate cancer（1）（2）（3）（4）｜Colon Cancer（1）（2）（3）（4）,Colonic Cancer/Liver Metastasis,Colon polyp｜Pulmonary adenocarcinoma（1）（2）｜Atopic dermatitis（1）（2）（3）｜Articular rheumatism（1）（2）（3）
｜Endometriosis｜ Bladder cancer,Bladder Carcinoma｜Primary Malignant Lymphoma of the Left Breast ｜Articular Rheumatism｜Lung Cancer/Lib Metastasis,Lung cancer (terminal)｜Stomach Cancer,Stomach cancer (scirrhous)｜Liver cancer｜Metastatic Lung Cancer｜Pancreas Cancer, Gallbladder and Liver Metastasis｜Ovarian tumor｜Malignant liver cancer,Malignant lymphoma｜Infantile asthma｜Tonsillitis｜Pharynx cancer｜Oropharynx cancer｜Rectum cancer, bile duct cancer｜Pulmonary adenocarcinoma→metast asis to the pleura
|
|
|
|
|
| No. 1 Chronic hepatitis
|
| NAME/N.M | AGE/48
| SEX/Male | RESIDENCE/Nagano
|
| Clinical Record and Treatment
|
|
In early March 1996, the patient felt unusual languidness, and had his chronic hepatitis (non-viral) and his slight diabetes diagnosed at H polyclinic.
The patient entered the clinic on May 30th, 1996. After rest and an intravenous injection for Major Minofargen C, his liver function came to a temporary lull and he left the clinic after one month.Thereafter, the patient experienced periodic deterioration in his liver functions in spite of continuing intravenous treatment for Major Minofargen C, and suffered from chronic hepatitis until the beginning of March 1997. The patient then started taking 3g of MGN-3 per day (1g/dose) and his level of liver function increased to nearly the same level as at the beginning of therapy 12 days earlier. The level gradually decreased, reaching the lowest value after one month. The patient's GOT and GPT levels returned to normal one month later. Presently, the patient's liver function has returned to normal, and the patient is experiencing no other health-related problems.
Changes due to MGN-3
The patient's energy level increased after MGN-3 administration, and his unusual fatigue (especially in the afternoon) gradually abated. The patient was able to sleep and wake normally, had a good appetite, and looked very healthy.
Evaluation
As indicated by the figure below, the GOT and GPT levels temporarily increased after the administration of MGN-3, before steadily decreasing and returning to normal. During MGN-3 administration, no special treatments were performed; therefore, it is possible to conclude that these changes were due to MGN-3. These results suggest that MGN-3 protected the patient's liver and its immunopotentiation function was effective. (Fig.)
|
|
| No.2 Cirrhosis
|
| NAME/K. H. | AGE/65
| SEX/Female | RESIDENCE/Hyogo
|
| Clinical Record and Treatment
|
|
In 1983, the patient was infected with hepatitis C by a blood transfusion conducted during an operation for uterine cancer. The patient was not convalescing satisfactorily and was suffered from cirrhosis of the liver. In 1992, the patient took a dose of interferon, but only suffered various side effects. At present, some of the cirrhosis symptoms such as liver cell dysfunction and liver fibrinogenerous have progressed slightly, but there has been no liver circulatory trouble thus far. The patient has taken 3g of MGN-3 daily (1g/dose) since April 1996.
Changes due to MGN-3
The patient has been able to sleep well since administration of MGN-3 began. Her appetite has improved and the patient has been able to evacuate easily. The patient's energy levels have improved after one week of treatment, and has been able to remain out of bed for longer periods of time. The patient gets up between 6:00 and 6:30 in the morning, and often goes out except when it is time for an intravenous drip, but does not feel excessively fatigued. Her frequency of urination at night has decreased.
Evaluation
As seen in the examination results for these two months, the patient's condition does not warrant any optimism. However, the patient herself is doing very well and enjoying her hobbies and volunteer work. Her doctor commented that her examination results were not necessarily consistent with her health condition. This suggests that MGN-3 can maintain proper liver functions and promote IF-γ due to NK cell activation.
|
| |
26/03/97 |
22/04/99 |
|
Total bilirubin |
|
1.3mg/dl |
|
GOT |
70 IU/l |
55 IU/l |
|
GPT |
72 IU/l |
47 IU/l |
|
LDH |
506 IU/l |
404 IU/l |
|
γ-GTP |
|
42 IU/l |
|
Albumin |
49.8% |
|
|
γ-globulin |
33.4% |
|
|
| No.3 Liver cancer
|
| NAME/N. K. | AGE/63
| SEX/Female | RESIDENCE/Hyogo
|
| Clinical Record and Treatment
|
|
In 1989, the patient was diagnosed with liver cancer at a hospital in Hyogo prefecture. Surgery was impossible due to the rapid spread of the disease. The patient's condition did not improve despite chemotherapy and actually worsened, as she also suffered from rhexis of esophageal varices and liver aneurysm. In August 1996, the patient's condition became desperate and in September she began taking 3g of MGN-3 per day. As of June 1997, the patient is receiving treatments based on holistic medicine at O hospital in Saitama prefecture.
Changes due to MGN-3
The patient had no success with various folk remedies and health foods, but got positive results from MGN-3. She recalls, "I feel an almost mysterious power. It is very hard to express the feeling, but I felt as if my body and the cancer could now co-exist."
|
|
| No.4 Diabetes
|
| NAME/K. M | AGE/64
| SEX/Male | RESIDENCE/Hyogo
|
| Clinical Record and Treatment
|
|
In September 17th, 1993, the patient was diagnosed with insulin-dependent diabetes mellitus at the City of H Hospital in Hyogo prefecture. His blood sugar level measured two hours after a meal was 331 mg/dl and his urea level was 1.0. As a result of the administration of insulin and a 2-month-hospitalization, his blood sugar level became normal, falling to 200mg/dl. Thereafter, the patient's blood sugar level was controlled using insulin. His urinary sugar level was also detected during administration. His blood sugar level started increasing again in September 1996, and finally reached 300 mg/dl in 1997. His urinary sugar level was also very high. The patient began taking the 2g of MGN-3 per day at 1g/dose. His blood sugar level decreased to 200 mg/dl while his urinary sugar level was not detected. Since February 1997, his blood sugar has remained stable between 150mg~180mg and he has not taken insulin since June 1997.
Changes due to MGN-3
After administration of MGN-3, the patient's urinary sugar level was not detected and he does not feel languid in the afternoon. His asthma has also gradually recovered. Furthermore, the patient is no longer susceptible to flu in the winter.
Evaluation
The patient's diabetic condition has gradually improved and at present his blood sugar level is stable and normal even without insulin. Although a synergistic relation between the recovery of diabetes and a dose of MGN-3 has yet to be fully proven, these results suggest some correlation. In addition, considering the patient's recovery from asthma and his newfound resistance against the flu, his immune system seems to have normalized. The MGN-3 effects in improving the immune system and its function as a dietary fiber might lead advances in the fight against diabetes. (Fig.)
|
|
| No.5 Prostate cancer
|
| NAME/F. N | AGE/78
| SEX/Male | RESIDENCE/Chiba
|
| Clinical Record and Treatment
|
|
In September 1994, the patient was diagnosed with prostate cancer diagnosed after experiencing dysuria and lumbago. The tumor widened from his lumbar region to his thoracic spine. In October 1994, the patient had an operation and began chemotherapy until December 1996. The patient kept taking AHCC at a dose of 2g/day from December 1995 to July 1996, while continuing with chemotherapy. In an examination on June 1996, his osteoncus had decreased to half the size of the original tumor, and all of his tumors had disappeared by December 1996. A tissue culture of the focus conducted in January 1997 revealed that the patient had recovered almost completely from cancer.
Changes due to MGN-3
Chemotherapy decreased the number of white and red blood cells, causing anemia. After the chemotherapy was discontinued, the patient started taking AHCC until the patient recovered from anemia and could continue chemotherapy. His appetite improved and the patient did not lose weight. His physical strength was maintained by taking AHCC and MGN-3, giving his body the energy to fight against the cancer.
|
|
| No.6 Endometriosis
|
| NAME/S. K | AGE/34
| SEX/Female | RESIDENCE/Hyogo
|
| Clinical Record and Treatment
|
|
The patient had felt lumber pain around her abdominal region and heavy lumbago since June 1996, and the pain worsened as the patient walked bending on herself. At first, her conditions were caused by constipation at a hospital. Then the patient had her endometriosis diagnosed at another hospital. While taking the medical examinations for a month, the patient did not receive any treatment except the administration of 3g of MGN-3 daily. As a result of the examinations, her uterus hypertrophy caused by the endometriosis pressed the ureter, which in turn placed excess pressure on her kidneys. Although doctors thought she might require an extirpation of her uterus, the pain eventually subsided sufficiently to allow her return to her normal lifestyle without any additional treatment. As of June 1997, the patient is in extremely good health.
Changes due to MGN-3
Five days after administration of MGN-3, the patient began forgetting her pain. After 1 month, the pain disappeared completely, as if the patient had never suffered from the disease.
|
|
| No.7 Diabetes
|
| NAME/T. T | AGE/55
| SEX/Male | RESIDENCE/Hyogo
|
| Clinical Record and Treatment
|
|
The patient was diagnosed with insulin-dependent diabetes mellitus in 1994. His blood sugar level was maintained between 157~160 mg/dl by taking 12 units of insulin per day. After the patient began taking 3g of MGN-3 per day, the administration of insulin was decreased to 6 units.
Changes due to MGN-3
On the fifth day after administration of MGN-3 was initiated, the patient fell into a hypoglycemia condition and insulin administration was reduced to 10 units. On the sixth day, the patient got hypoglycemia again and the insulin dosage was reduced to 8 units. The third hypoglycemic condition occurred on the 25th day, and the insulin dosage was reduced to 6 units. Since then, there has been reoccurrence of the patient's hypoglycemic condition. The patient feels cured of diabetes and has declared his life worth living again.
|
|
| No.8 Prostate Cancer
|
| NAME/C. J. | AGE/68
| SEX/Male | RESIDENCE/U. S. A.
|
| Clinical Record and Treatment
|
|
In July 1995, the patient was diagnosed with prostate cancer diagnosed at Drew University Hospital in California, and began receiving two types of chemotherapy treatments. These treatments yielded little improvement, and an examination conducted on August 25, 1995 revealed a Gleason score of 9. There was no significant recovery despite the chemotherapy, and the patient started taking 3g of MGN-3 per day in January 1996. In April 1996, the patient had a cryoprostatectomy, without receiving any hormone therapy. The patient recovered his ability to ejaculate on November 10, 1996. His NK activity increased after one year of treatment with MGN-3, and his tumor marker PSA level shows that the cancer is in full remission. (Fig.)
Evaluation
The patient started taking MGN-3 after it was clear that chemotherapy was not effective. Three months later, due to the involution of the tumor, it became possible to remove the tumor through a cryoprostatectomy. The MGN-3 likely contributed to the restoration of the patient's ability to ejaculate. His NK activity has been maintained by the administration of MGN-3, and the results suggest that MGN-3 had a positive influence in preventing the return of the disease and in inducing the involution of the tumor.
|
|
| No.9 Breast Cancer
|
| NAME/M. L. | AGE/50
| SEX/Female | RESIDENCE/U. S. A.
|
| Clinical Record and Treatment
|
|
On August 3, 1991, a tumor was found in the patient's left breast during a tissue examination. The patient started taking 3g of MGN-3 per day as immunotherapy on September 3, 1992. Subsequently, a CAT scan performed on March 13, 1993 found no tumor. The patient's right breast was also normal and healthy, as indicated by a mammography conducted on January 26, 1995. (Fig.)
Evaluation
The administration of MGN-3 completely healed the patient's breast cancer within two years. Her NK cell activity increased rapidly and remained at a high level during MGN-3 administration. The immunity developed as a result of MGN-3 intake appeared to heal the patient's breast cancer.
|
|
| No.10 Breast Cancer
|
| NAME/C. E. | AGE/51
| SEX/Female | RESIDENCE/U. S. A.
|
| Clinical Record and Treatment
|
|
On December 19, 1994, a tumor was found in the patient's left breast during a biopsy at UCLA/Drew university hospital. The patient started taking 3g of MGN-3 per day (1g/dose) on March 7, 1995. By July 31, 1995 a mammography revealed no tumors, not even a benign one. By January 1997, no tumor was detected. (Fig.)
Evaluation
After failing to improve despite Hormonotherapy and Radiotherapy treatments, the patient took MGN-3 in order to prevent relapses. NK cell activity has increased since the start of MGN-3 administration, nearly doubling since administration began.
|
|
| No.11 Breast Cancer
|
| NAME/C. E. | AGE/51
| SEX/Female | RESIDENCE/U. S. A.
|
| Clinical Record and Treatment
|
|
On December 19, 1994, a tumor was found in the patient's left breast following a biopsy at Drew University Hospital, CA. The patient started hormone therapy with Tomoxifen on January 20, 1995. The patient ended irradiation therapy on February 17, 1995 and began receiving 3 g MGN-3 per day (1g/dose) on March 7, 1995. No tumor, benign or otherwise, was found after a mammography on July 31, 1995. No tumor was found in the patient's breast during an examination in January 1997. (Change in NK activity due to MGN-3 intake, cf. Fig.)
Evaluation
After receiving hormone therapy and irradiation therapy, the patient took MGN-3 in order to prevent the recurrence of cancer. While taking MGN-3, the patient's NK cell activity has increased gradually and the patient has been maintaining twice the level of NK cell activity as first measured. This result is thought to have helped prevent recurrence.
|
|
|
|
